Mechanism of Action: Abraxane
Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is a microtubule inhibitor.
Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is a microtubule inhibitor indicated for the treatment of:
- Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Recent Videos
Related Content
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024Article
TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More
